Project Grant R01HL180336
Award Date 8/15/25
Completion Date 5/31/30
Dollars Obligated $726K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $536,468 to the University of California, San Diego (UC San Diego) to conduct research on protein aggregation in hematopoietic stem cells (HSCs). The project aims to investigate how HSCs, which regenerate blood and immune cells, preferentially traffic misfolded proteins to aggresomes to maintain fitness and self-renewal, and how this process is impacted by...
- This Project Grant award from the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837) provides $814,209 to the Fred Hutchinson Cancer Center to support research on the use of targeted nanoparticles for in vivo hematopoietic stem cell gene therapy. The project aims to refine the target for hematopoietic stem cell gene therapy and develop a method to genetically modify these cells directly in the patient, which would improve the feasibility...
- The University of California, Davis received a $400,417 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to conduct research on cardiac regenerative therapy using gene-edited stem cells. The goal is to improve transplantation outcomes and address the critical role of inflammation-induced cell death that impedes current cardiac stem cell therapies. The research aims to develop new treatments for end-stage heart failure, a...
- This $2,024,340 Project Grant was awarded on August 15, 2025 by the National Heart Lung and Blood Institute (NHLBI), part of the National Institutes of Health, under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The grant supports a multi-year research effort at Boston Children's Hospital to optimize outcomes for hematopoietic stem cell transplantation (HCT), an essential treatment for high-risk non-malignant and malignant hematologic diseases. The research project...
- This Project Grant award of $207,740.00 from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to develop a machine learning model that can predict permissive human leukocyte antigen (HLA) mismatches for hematopoietic stem cell transplants (HCT) using post-transplant cyclophosphamide (PTCY) for graft-versus-host disease (GVHD) prophylaxis. The goal is to improve HCT utilization and outcomes for ethnic minority patients who face disparities in donor...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $131,211 to The Leland Stanford Junior University to conduct research on high-resolution tracking of T cell differentiation to predict and control alloreactive disease in allogeneic hematopoietic stem cell transplantation (allo-HSCT). The grant, which has a performance period from July 15, 2025 to June 30, 2027, aims to identify alloreactive T cell subsets...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $497,806.97 in funding to support research to improve the functional competency and/or number of hematopoietic stem cells (HSCs) derived from umbilical cord blood. The goal is to elucidate molecular programs that can be targeted to enhance cord blood HSC function and generate preliminary data to support a future competitive R01 grant...
- This Project Grant award of $125,532.00, provided by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), aims to investigate the disruption of the clonal architecture of human hematopoietic stem cells driven by high-effect somatic and germline genetic variants, and identify the resulting phenotypic changes that lead to impaired stem cell function and increased disease risk with aging. The research will utilize a mitochondrial lineage tracing...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $162,486 to The Leland Stanford Junior University to engineer hematopoietic stem cells to produce B cells that secrete antibodies against PCSK9, a promising treatment for hypercholesterolemia. The research aims to develop a durable, lifelong therapeutic solution by using CRISPR/Cas9 genome editing to target an engineered antibody transgene into a safe-harbor site in...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $680,321 to the Fred Hutchinson Cancer Center in Seattle, Washington to conduct research on the role of the DLK1 protein in regulating hematopoietic stem cell (HSC) quiescence. The research aims to further assess the effects of DLK1 on HSC maintenance and expansion, and elucidate the mechanism by which DLK1 inhibits receptor-mediated...